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Objective/Background: Progesterone-receptor negativity (PR) is predictive of adverse out-
comes in estrogen receptor-positive (ER+) breast cancer. The Oncotype DX assay provides risk
stratification for hormone receptor-positive (HR+) invasive breast cancer; however, the associ-
ation of PR status and Oncotype DX recurrence scores (RSs) is less clear.
Methods: We designed an analysis to determine whether a significant difference exists in the
RS for ER+/PR tumors when compared with ER+/PR+ breast cancer. Three hundred and fifty
patients with HR+ invasive breast cancer who underwent Oncotype DX testing at our institution
from December 2006 to October 2013 were included. We also examined the concordance in the
HR status reported by immunohistochemical (IHC) and reverse transcriptase-polymerase chain
reaction (RT-PCR) analyses. The data were analyzed by analysis of variance, F test, t test, and
chi-square tests. Multivariate linear regression was used to determine significant predictors of
Oncotype DX RS.
Results: A total of 301 patients had ER+/PR+ tumors and 47 patients had ER+/PR tumors by
IHC. PR tumors had a significantly higher RS than PR+ tumors (24.7 ± 8.53 vs. 17.3 ± 7.38;
p < .001), predicting a greater 10-year risk of distant recurrence. Multivariate linear regression
showed PR status and tumor grade to be significant predictors of Oncotype DX RS (p < .0001). Ain Avenue,
PR-negative breast cancer and Oncotype DX recurrence scores 49total of 284 patients had HR status reported by Oncotype DX assay. Concordance between IHC
and RT-PCR was 99.3% for ER and 88.7% for PR.
Conclusion: Our study shows that ER+/PR breast cancer tumors are associated with a signif-
icantly higher Oncotype DX scores; this interprets into a higher risk of recurrence. Our data also
show that the concordance between IHC and RT-PCR was 99.3% for ER and lower at 88.7% for
PR.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
The management of breast cancer has advanced signifi-
cantly with recognition of its molecular subtypes. Current
approaches merge clinical, pathological, and molecular
understanding of this tumor with a better grasp of therapeu-
tic efficacy and outcomes. Estrogen and the estrogen recep-
tor (ER) play key roles in normal breast development and
the development of breast cancer. The progesterone recep-
tor (PR) is present in both normal and malignant cells in the
breast and its synthesis is dependent on both estrogen and
the ER. Approximately 75% of primary breast cancers
express ER, whereas more than half of these cancers also
express PR [1]. However, within the group of ER+ tumors
is the ER+/PR subtype, which is now recognized as a dis-
tinct biological and clinical entity associated with a less
favorable outcome. Recent studies have shown that the
absence of PR is an independent predictor of poor response
to antiestrogen therapy, and is associated with higher recur-
rence rates and shorter survival time [2].
Risk assessment is crucial to avoid overtreatment of
patients with primary breast cancer. Gene expression profil-
ing has emerged as a useful tool for assessing the risk of dis-
tant disease recurrence in patients with early stage breast
cancer as it provides additional information to the tradi-
tional clinicopathological factors and biomarkers in clinical
decision making [3–8]. The 21-gene Oncotype DX assay is a
validated genomic test that quantifies the risk of distant
recurrence at 10 years from diagnosis and the potential
benefit of chemotherapy in early stage ER+ breast cancer
[9–11].
In contrast to ER+/PR+ breast tumors, ER+/PR tumors
display greater genomic instability that may explain, in
part, their poorer prognosis than ER+/PR+ tumors [12].
However, the association of PR status per se with Onco-
type DX recurrence scores (RSs) has not been extensively
reviewed. We, therefore, conducted a retrospective study
to evaluate the association of PR tumors with Oncotype
DX RSs with the primary objective to assess whether a signif-
icant difference exists in the RS for PR tumors when com-
pared with PR+ tumors. Since 2008, the Oncotype DX reports
have also included ER, PR, and HER2 qualitative and quanti-
tative results. Our secondary objective was to compare the
results of ER and PR determination by traditional immuno-
histochemical (IHC) methods with the result of ER and PR
determination by the Oncotype DX assay which employs a
reverse transcriptase-polymerase chain reaction (RT-PCR)
assay to quantitate hormone receptor (HR) status of breast
tumors. This objective sought to determine the level ofconcordance in the status of hormone receptors reported
by the two methods.
Methods
Patient population and data collection
A retrospective review analysis was performed to determine
whether the Oncotype DX RSs differ between ER+/PR+ and
ER+/PR tumors. A total of 350 patients with hormone
receptor-positive, node-negative invasive breast cancer
who underwent Oncotype DX testing at our institution
between December 2006 and October 2013 were included
in our study. We identified 284 patients in whom the Onco-
type DX assay also included an analysis of hormone receptor
status in addition to the RS. Additional patient data col-
lected included age, menstrual status, tumor pathology
(i.e., histology, grade, and receptor status), breast cancer
stage, and treatments received including surgery, radiation,
chemotherapy, and endocrine therapy. The study was
approved by the Institutional Review Board and the Protocol
Review and Monitoring Committee of the Medical College of
Wisconsin, WI, USA.
IHC analysis of the primary tumor
ERs and PRs were evaluated by IHC on formalin-fixed
paraffin-embedded tissue using clone 1 D5 for ER and clone
PgR 636 for PR (Dako, Carpinteria, CA, USA). In 2008, our
institution switched to clone SP1 for ER and clone SP2 for
PR (Ventana, Tucson, AZ, USA). Detection utilized a mono-
clonal polymer. Prior to 2012, appropriate nuclear staining
in P10% of the cells of interest was considered positive,
whereas <10% was considered negative for the ER or PR. In
2012, the nuclear staining criteria were revised to consider
any nuclear staining inP1% of the malignant cells to be pos-
itive and <1% to be considered negative for the ER or PR.
Oncotype DX assay
The Oncotype DX RS is reported to represent the likelihood
of breast cancer relapse within 10 years in patients treated
with tamoxifen for 5 years [7,11]. Patients at low, interme-
diate, and high risk for relapse are defined as having an RS of
0–17, 18–30, and 31–100, respectively [7]. The Oncotype
DX assay uses the following expression units criteria for
hormone receptor and HER2 expression: ER negative <6.5,
ER positive P6.5, PR negative <5.5, PR positive P5.5,
50 L.N. Chaudhary et al.HER2 negative <10.7, HER2 equivocal P10.7–11.4, and
HER2 positive P11.5.
Statistical analysis
Continuous variables were compared using t tests. Wilcoxon
rank-sum test was used for ordinal data. Multivariate linear
regression was used to determine significant predictors of
Oncotype DX scores. Covariates included in the regression
model were age, menopausal status, tumor size, tumor his-
tology, grade, ER status, and PR status. Chi-square test was
used to analyze the discrepancies between the two methods
to assess concordance of HR results. All statistical tests with
two-sided p < .05 were considered statistically significant.
Statistical analysis was completed using SAS version 9.3
(SAS Institute, Cary, NC, USA).Table 1 Patient characteristics relative to hormone receptor st
Variables
Age at DX
Mean ± standard deviation
Menstrual status
Menopausal
Premenopausal
Histology
Invasive ductal carcinoma
Invasive lobular carcinoma
Grade
1
2
3
Stage
T1a
T1b
T1c
T2
T3
Surgery
Lumpectomy
Mastectomy
None
Chemotherapy
Yes
No
Endo tx
AI
Tam
Switch AI and Tam
Luteinizing hormone releasing hormone agonists
None
AI = aromatase inhibitor; ER = estrogen receptor; PR = progesterone re
* t test.
** Chi-square test.
*** Wilcoxon rank-sum test.Results
Patient characteristics
This study included 350 patients. The mean age at diagnosis
was 58 years (58 ± 10.1 mean ± standard deviation [SD]). Of
the 350 patients, 301 had PR + disease and 47 patients had
PR tumors by IHC. Receptor information was missing for
two patients, and they were not included in the analysis.
Most patients were postmenopausal (70%) and had invasive
ductal carcinoma (84%). As much as 60% of patients had
Grade 2 tumors, and 57% of patients had T1c tumors. All
patients had tumors that were ER+ by IHC and node nega-
tive. Other patient characteristics relative to hormone
receptor status are presented in Table 1.atus.
ER+/PR+
N = 303 (%)
ER+/PR
N = 47 (%)
p
.542*
58.1 ± 10.2 59.1 ± 9.5
.041**
207 (68.3) 39 (83.0)
96 (31.7) 8 (17.0)
.424**
248 (82.4) 44 (93.6)
50 (16.6) 3 (6.4)
.183***
103 (34.1) 11 (23.4)
176 (58.3) 32 (68.1)
23 (7.6) 4 (8.5)
2 (0.7) 2 (4.2)
49 (16.2) 9 (19.1)
174 (57.5) 25 (53.3)
74 (24.5) 11 (23.4)
2 (0.7) 0 (0.0)
.056**
198 (65.6) 30 (63.8)
102 (33.8) 17 (36.1)
3 (0.6) 0 (0.0)
93 (30.4) 32 (68.1)
210 (69.6) 15 (31.9)
167 (55.4) 30 (65.2)
89 (29.2) 9 (19.5)
36 (10.9) 4 (8.8)
2 (0.6) 0 (0.0)
7 (2.3) 3 (6.5)
ceptor; Tam = tamoxifen.
PR-negative breast cancer and Oncotype DX recurrence scores 51PR status and Oncotype DX RS
Univariate analysis showed that PR tumor status was asso-
ciated with significantly higher Oncotype DX scores when
compared with PR+ tumors (mean ± SD, 24.7 ± 8.53 vs.
17.3 ± 7.38; p < .001), thereby predicting a greater 10-year
risk of distant recurrence. Most of the patients with
PR tumors had intermediate or high Oncotype DX RSs
[53.2% (n = 25) and 27.7% (n = 13), respectively],
compared with PR+ tumors, which were associated more
with low and intermediate RSs [53.5% (n = 161) and 41.2%
(n = 124), respectively]. Only 5.3% (n = 16) of patients with
ER+/PR + tumors had a high Oncotype DX RS as shown in
Table 2.
Grade and Oncotype DX RS
Higher tumor grade was associated with a higher Oncotype
DX score when compared with intermediate- and low-
grade tumors (18.9 ± 8.6 vs. 16.2 ± 6.7; p = .024) and (23.3
± 9.6 vs. 16.2 ± 6.7; mean ± SD; p < .0001), respectively, as
shown in Fig. 1.Table 2 Association of PR status with Oncotype DX recurrence s
Variables ER+/PR+
N (%)
Recurrence score
N 301
Mean ± standard deviation 17.3 ± 7.38
Recurrence score
Low 161 (53.5)
Intermediate 124 (41.2)
High 16 (5.3)
ER = estrogen receptor; PR = progesterone receptor.
* t test.
** Chi-square test.
Fig. 1 Association of tumor graHistology and Oncotype DX RS
We also evaluated the association of histology, that is, inva-
sive lobular breast cancer versus invasive ductal breast can-
cer, with Oncotype DX scores. No significant difference in
Oncotype DX scores was seen based on histology of breast
cancer (p = .23).
IHC clone and Oncotype DX RS
Our institution used clone 1 D5 for ER and clone PgR 636 for
PR (Dako) IHC staining until 2008 when we switched to clone
SP1 for ER and clone SP2 for PR (Ventana). There was no sig-
nificant difference in the Oncotype DX scores based on the
different clones and staining criteria used (18.6 ± 6.55 vs.
17.9 ± 8.86; mean ± SD, p = .75).
Multivariate linear regression analysis
PR status was a significant predictor of Oncotype DX RS
(p < .0001). Higher tumor grade was also associated with a
higher Oncotype DX score (p < .0001). Age, menstrualcores.
ER+/PR
N (%)
p
<0.001*
47
24.7 ± 8.53
<0.001**
9 (19.1)
25 (53.2)
13 (27.7)
de with Oncotype DX score.
Fig. 2 Concordance between immunohistochemistry (IHC) and reverse transcriptase-polymerase chain reaction (RT-PCR).
ER = estrogen receptor; PR = progesterone receptor.
52 L.N. Chaudhary et al.status, tumor histology, and size were not significant
predictors of Oncotype DX RS.
Concordance in hormone receptor assessment by
IHC and RT-PCR
A total of 284 patients in our study had hormone receptor
status reported by Oncotype DX assay. When comparing
IHC and Oncotype DX assay, 20 patients (8.1%) who were
ER+/PR+ by IHC were found to have ER+/PR tumors by
RT-PCR. Of the ER+/PR cases identified by IHC, 12
(31.6%) patients were ER+/PR+ and two (5.3%) patients were
ER/PR by RT-PCR (p < .001), as shown in Fig. 2 and
Table 3. ER was concordant between IHC and RT-PCR in
99.3% of cases. However, the concordance for PR between
the two methods was lower at 88.7%.Table 3 Concordance between IHC and Oncotype DX
hormone receptor results.
RT-PCR IHC p
ER+/PR+
N (%)
ER+/PR
N (%)
ER+/PR+ 226 (91.9) 12 (31.6) <0.001*
ER+/PR 20 (8.1) 24 (63.2)
ER-/PR 0 (0.0) 2 (5.3)
ER = estrogen receptor; IHC = immunohistochemistry; PR = pro-
gesterone receptor; RT-PCR = reverse transcriptase polymerase
chain reaction.
* Chi-square test.Discussion
Tremendous progress has been made in the treatment of
breast cancer. A wealth of knowledge acquired in the last
decade in the field of molecular endocrinology, tumor biol-
ogy, and genomic medicine has led to substantial improve-
ments in the efficacy of cancer treatment and prevention.
Determining ER, PR, and HER2 status is crucial to optimizing
treatment outcomes in breast cancer patients. Loss of PR is
associated with a more aggressive tumor phenotype and
earlier tamoxifen resistance. Retrospective analysis from
the Arimidex, Tamoxifen, Alone or in Combination (ATAC)
trial showed that patients with ER+ PR tumors derived less
benefit from tamoxifen therapy when compared to anastro-
zole [13]. This benefit was not seen in the TransATAC anal-
ysis, although PR expression continued to be a significant
predictor of outcome for both anastrozole and tamoxifen
therapy, leading to the conclusion that the expression of
PR has an intrinsic prognostic effect [14]. Rakha et al. [2]
demonstrated that ER+/PR tumors are more frequently
seen in elderly postmenopausal women and that the
absence of PR was an independent predictor of recurrence
and shorter survival. Other studies have also shown that
ER+/PR tumors were larger in size, more likely to be
higher grade, and to display HER2 gene amplification
[15,16].
The Oncotype DX assay developed by Genomic Health
(Redwood City, CA, USA) offers additional prognostic and
predictive information to ER+ lymph node-negative breast
cancer patients as well as ER+ lymph node-positive post-
menopausal patients [9,10]. Although a number of studies
have shown the value of Oncotype DX RS in assisting
clinical decision making for breast cancer management
[10,11,17–20], only a few studies have focused on the
PR-negative breast cancer and Oncotype DX recurrence scores 53relationship between established clinicopathological vari-
ables and the RS. Clark et al. [21] in their quality assurance
study of 1074 cases reported that a higher PR expression was
associated with a lower Oncotype DX RS and this inverse
relationship was independent of tumor grade. Auerbach
et al. [22] analyzed the relationship between RS and compo-
nents of routine pathologic assessment in lymph node-
negative, ER+ invasive breast cancer patients (N = 138). In
their study, 13/138 cases had a high RS, of which 10 were
PR and three were PR+ but with a high Nottingham Grade
of 3. All other cases that were either PR or had Grade 3
tumors had at least an intermediate-risk RS. In another
study of 77 cases of invasive breast cancers in which the vast
majority were ER+/PR+, all six PR cases had intermediate-
risk or high-risk RS [23].
Our study provides further validation to the inverse rela-
tionship between PR receptor status and Oncotype DX RS.
Oncotype DX RS is predictive of patient’s benefit from adju-
vant chemotherapy in both the low and high RS categories
based on the rate of distant recurrence at 10 years. How-
ever, the data and suggested treatment strategy for inter-
mediate RS patients are less clear and will likely remain
so until the results from the Trial Assigning IndividuaLized
Options for Treatment (TAILORx) trial become available
[24]. When weighing the treatment options for the patients
in the intermediate RS category, the PR status may be an
important factor to consider in clinical decision making.
PR breast cancer likely represents a luminal B subtype that
is associated with a more aggressive disease course and a
greater likelihood of endocrine resistance when compared
with PR+ tumors. Thus, patients with ER+/PR breast can-
cers may be considered for adjuvant chemotherapy if they
belong to the intermediate-risk category.
ER and PR status is an important factor in determining
whether a patient will benefit from antiestrogen therapy.
According to the American Society of Clinical Oncology/Col-
lege of American Pathologists, validated techniques to
assess these biomarkers are IHC and fluorescence in situ
hybridization [25,26]. Since 2008, the qualitative and quan-
titative results for ER, PR, and HER2 have been included in
the Oncotype DX report. With supplemental reporting of
these biomarkers, there has been growing interest in molec-
ular testing by RT-PCR. Conflicting views on the utility of
Oncotype DX as a test to accurately measure these biomark-
ers have been recently published [27–30]. Badve et al. [29]
compared central IHC analysis results for ER and PR with
Oncotype DX RT-PCR assay for 776 cases from the Eastern
Cooperative Oncology Group (ECOG) 2197 trial. For ER,
the concordance between central IHC and RT-PCR was
93%, whereas for PR the concordance was 88%. Park et al.
[24] reported 98.9% concordance for ER and 91.3% concor-
dance for PR when IHC and RT-PCR were compared in 265
breast cancer patients. In another study of 464 breast can-
cer cases, comparison of hormone receptor status reported
by IHC and RT-PCR showed a good concordance of 98.9% for
ER and 94.2% for PR status [28]. The authors also concluded
that IHC was slightly more sensitive at determining the ER
and PR expression. Similar to the previously published data,
our study showed good concordance of 99.3% for ER status
when comparing IHC with RT-PCR. However, the concor-
dance for PR status was lower at 88.7%. This is comparable
with the results published by Badve et al. [29]; however, itis much lower than other published studies. One of the
hypotheses for the lower concordance for PR status was
the change in the clones used to generate the ER and PR
antibodies used for IHC and the staining criteria within the
period of our study at our institution. However, our analysis
and group-wise comparisons did not show any significant dif-
ference in Oncotype DX scores and concordance rates
between the different clones used and the staining criteria.
Some limitations of our study are the relatively small
number of patients and retrospective design. Nonetheless,
our findings appear to be plausible and warrant confirmation
in further studies with larger number of patients. Such stud-
ies would help elucidate the value of PR expression in recur-
rence risk determination and would assist clinicians in
therapeutic decision making and avoidance of undertreat-
ment or overtreatment of early stage breast cancer.
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